SBIR/STTR Research Award
Human Induced Pluripotent Stem Cell-Derived Beta-Cells for Drug and Toxicity Testing
Award amount
$222,020Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Regenerative Medical Solutions Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- WK5KJPECBBA3
- Solicitation number
- PA14-071
- Topic code
- NIDDK
Research abstract
? DESCRIPTION (provided by applicant): Diabetes represents one of the most serious health crises worldwide. It is estimated by the American Diabetes Association that one person is diagnosed with diabetes every 17 seconds, while the International Diabetes Federation states that one person dies every seven seconds from diabetes. Diabetes growth continues to skyrocket, with over 382 million cases worldwide, and according to the Centers of Disease Control, one out of every three Americans will have Type IIdiabetes by 2050. Replacement of deficient ? cells with human islets has proven successful in treating diabetes. Unfortunately, the high cost, unpredictable availability, and variable quality of human islets hinder wide spread application. Thus, an abundant supply of high-quality ?-like cells generated from human pluripotent stem cells (hPSCs) has tremendous implications for both therapeutic application and the development of drug discovery platforms. RMS has developed and marketed a novel in vitro differe
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells
- Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance
- Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells
- Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications
- Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
8 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $3,838,950. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services